SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease

Yang, Chunru; Xiao, Cheng; Zhai, Xiaojun; Liu, Jieying; Yu, Miao

doi:10.1016/j.jdiacomp.2023.108652

Journal of Diabetes and its Complications

2024

DOI: 10.1016/j.jdiacomp.2023.108652

|View full text |Cite

SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease

Chunru Yang,

Cheng Xiao,

Xiaojun Zhai

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density

Pradhan,

Kalanski,

Tintut

et al. 2024

Current Opinion in Lipidology

View full text Add to dashboard Cite

Purpose of review Inhibitors of sodium-glucose cotransporter-2 (SGLT2) lower renal glucose reabsorption and, thus, are used to treat patients with type 2 diabetes mellitus. Clinical trials coincidentally showed that SGLT2 inhibitors also benefitted patients with heart failure. This review explores the impact of SGLT2 inhibitors on other aspects of cardiovascular disease and skeletal health. Recent Findings In some, but not all, clinical and preclinical studies, SGLT2 inhibitors are found to reduce serum levels of free fatty acids and triglycerides. Their effects on total and low-density lipoprotein cholesterol and cardiac function also vary. However, SGLT2 inhibitors reduce lipid accumulation in the liver, kidney, and heart, and alter expression of lipid metabolism genes. Effects on free fatty acid uptake in abdominal fat depots depend on the location of adipose tissue. In male, but not female, mice, SGLT2 inhibitors reduce the atherosclerotic lesions and aortic calcium deposition. With respect to skeletal health, recent literature has reported conflicting associations with the risks of fracture and amputation. Summary Studies suggest that SGLT2 inhibitors reduce tissue lipid accumulation, and in a sex-dependent manner, atherosclerosis and vascular calcification. However, their effects on lipid levels and bone health are complex and remain to be established.

show abstract

Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density

Pradhan,

Kalanski,

Tintut

et al. 2024

Current Opinion in Lipidology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease

Cited by 1 publication

References 34 publications

Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density

Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density

Contact Info

Product

Resources

About